Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research

Study Design

Type
Systematic Review
Population
HIV-infected adults
Methods
systematic review and meta-analysis by searching PubMed, EmBase, Web of Science, and Cochrane Library; data pooled using random-effects or fixed-effects models

Background

Moringa oleifera (MO) is widely used as an adjunctive therapy for individuals living with HIV (PLWH) due to its nutritional and immune-modulating properties.

Objective

To systematically evaluate the effects of MO supplementation on immune and nutritional indicators in Human Immunodeficiency Virus (HIV)-infected adults.

Methods

We conducted a systematic review and meta-analysis by searching PubMed, EmBase, Web of Science, and Cochrane Library to include studies assessing the impact of MO supplementation on immune and nutritional markers, such as CD4+ T cell count, BMI, white blood cell (WBC) count, and platelet (PLT) count in PLWH. Data were pooled using random-effects or fixed-effects models, and subgroup and meta-regression analyses were performed to assess sources of heterogeneity.

Results

A total of seven articles (eight study datasets) were included. MO supplementation significantly increased CD4+ T cell count [standardized mean differences (SMD) = 1.4, 95% CI 0.59-2.20, p < 0.001], WBC (SMD = 0.22, 95% CI 0.02-0.42, p = 0.030), and PLT count (SMD = 3.14, 95% CI 2.37-3.92, p < 0.001), with a significant improvement in BMI (SMD = 0.29, 95% CI 0.03-0.55, p = 0.028). Subgroup analysis demonstrated consistent effects in both randomized controlled trials (RCTs) and non-RCTs, while meta-regression indicated that dosage influences outcomes (p = 0.007). Further studies with larger sample sizes are warranted.

Conclusions

MO supplementation significantly improves immune function and nutritional status in PLWH. Further high-quality studies are needed to confirm its efficacy and safety.

Systematic review registration

https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD420251000927, PROSPERO: CRD420251000927.

Research Insights

Back to top